Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer

Oncologist - United States
doi 10.1634/theoncologist.2018-0243
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Androgen Receptor-Positive, Triple-Negative Breast Cancer

Cancer
Cancer ResearchOncology
2017English

Phase 1b Study of Orteronel in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic Breast Cancer

Investigational New Drugs
OncologyPharmacology
2016English

Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer

Scientific Reports
Multidisciplinary
2017English

A Prospective Phase II Study of Combined Androgen Blockade in Patients With Androgen Receptor-Positive Metastatic or Locally Advanced Unresectable Salivary Gland Carcinoma

Annals of Oncology
MedicineOncologyHematology
2018English

Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2−negative Endocrine-Refractory Metastatic Breast Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Prohibitin Promotes Androgen Receptor Activation in ER-positive Breast Cancer

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2017English

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

The Androgen Receptor in Breast Cancer

Frontiers in Endocrinology
EndocrinologyMetabolismDiabetes
2018English

Androgen Receptor in Male Breast Cancer

Polish Journal of Pathology
MedicineForensic MedicinePathology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy